ADJUVANT ORAL RAZOXANE (ICRF-159) IN RESECTABLE COLORECTAL-CANCER

被引：0
|
作者：
GILBERT, JM
HELLMANN, K
EVANS, M
CASSELL, PG
STOODLEY, B
ELLIS, H
WASTELL, C
机构：
[1] WEXHAM PK HOSP,SLOUGH,ENGLAND
[2] WESTMINSTER HOSP,LONDON SW1P 2AP,ENGLAND
[3] IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND
[4] EASTBOURNE DIST HOSP,EASTBOURNE,ENGLAND
来源：
CANCER CHEMOTHERAPY AND PHARMACOLOGY | 1982年 / 8卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：293 / 299
页数：7
相关论文
共 50 条
  • [21] SOMATIC-CELL HYBRIDIZATION STUDIES ON THE NATURE OF CELLULAR-RESISTANCE TO ICRF-159 (RAZOXANE)
    EDGAR, DH
    CREIGHTON, AM
    BRITISH JOURNAL OF CANCER, 1980, 42 (01) : 186 - 186
  • [22] RAZOXANE ADJUVANT CHEMOTHERAPY IN DUKES-C COLORECTAL-CANCER
    HELLMANN, K
    GILBERT, JM
    IRWIN, JTC
    EVANS, M
    CASSELL, PG
    BRITISH JOURNAL OF CANCER, 1989, 59 (05) : 826 - 826
  • [23] THE EFFECTS OF RAZOXANE (ICRF-159) ON THE PRODUCTION OF COLLAGENASE AND INHIBITOR (TIMP) BY STIMULATED RABBIT ARTICULAR CHONDROCYTES
    DUNCAN, SJ
    REYNOLDS, JJ
    BIOCHEMICAL PHARMACOLOGY, 1983, 32 (24) : 3853 - 3858
  • [24] CYTOGENIC EFFECTS OF RAZOXANE (ICRF-159) AND ITS STRUCTURAL ANALOGS IN CULTURED HUMAN-LYMPHOCYTES
    ALBANESE, R
    HUMAN TOXICOLOGY, 1985, 4 (05): : 542 - 542
  • [25] ICRF-159 (RAZOXANE) IN PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE ENDOMETRIUM - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
    HOMESLEY, HD
    BLESSING, JA
    CONROY, J
    HATCH, K
    DISAIA, PJ
    TWIGGS, LB
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1986, 9 (01): : 15 - 17
  • [26] ICRF-159 (RAZOXANE) IN THE TREATMENT OF PEDIATRIC SOLID TUMORS - SOUTHWEST-ONCOLOGY-GROUP STUDY
    DYMENT, PG
    STARLING, KA
    LAND, VJ
    CANGIR, A
    KOMP, DM
    SEXAUER, CL
    CANCER TREATMENT REPORTS, 1979, 63 (08): : 1397 - 1398
  • [27] BIOAVAILABILITY IN MAN OF ICRF-159 A NEW ORAL ANTINEOPLASTIC AGENT
    CREAVEN, PJ
    ALLEN, LM
    ALFORD, DA
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1975, 27 (12) : 914 - 918
  • [28] TRIAZINATE (T), ICRF-159 (I), 5-FLUOROURACIL (F) AND METHYLCCNU (M) IN THE COMBINATION CHEMOTHERAPY OF ADVANCED COLORECTAL-CANCER
    BERENZWIEG, M
    QAZI, R
    VOGL, SE
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 398 - 398
  • [29] THE PATHOMORPHOLOGY OF DAUNORUBICIN-INJURED AND ICRF-159 (RAZOXANE)-PROTECTED MURINE MYOCARDIUM - PROGRESS REPORT
    FISCHER, VW
    LAROSE, LS
    WANG, GM
    JOURNAL OF THE AMERICAN COLLEGE OF TOXICOLOGY, 1984, 3 (02): : 175 - 187
  • [30] REDUCTION OF CHRONIC DOXORUBICIN CARDIOTOXICITY IN BEAGLE DOGS BY BIS-MORPHOLINOMETHYL DERIVATIVE OF RAZOXANE (ICRF-159)
    HERMAN, EH
    FERRANS, VJ
    BHAT, HB
    WITIAK, DT
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1987, 19 (04) : 277 - 281
12345